Protocol Ledger

NCT06680921 · Phase III · ACTIVE NOT RECRUITING

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Interventional Phase III clinical trial protocol NCT06680921 sponsored by Jiangsu Simcere Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-14 Enrollment: 482 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06680921
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)482 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06680921
Protocol FieldVerified Registry Value
NCT IdentifierNCT06680921
Consolidated Lead SponsorJiangsu Simcere Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment482 participants (ACTUAL)
Registered Start Date2024-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI